Clinical Roundup

Clinical Roundup

Quest Diagnostics report shows oncologists see more advanced cancers, say current tests not catching recurrence early enough

According to a recent report, “The Cancer Paradox: Oncologists’ Perspectives on Barriers to Advanced Cancer Care and Recurrence Monitoring,” oncologists believe they are seeing more and more patients with advanced cancers, and that screening barriers are the leading reason why. They worry that current tests may not catch cancer recurrence early enough.
Clinical Roundup

Durvalumab regimen demonstrates improvement in DFS for high-risk NMBIC in phase III trial

Positive high-level results from the POTOMAC phase III trial showed one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer compared to BCG induction and maintenance therapy alone.​